Professor Emeritus Knut Dahl-Jørgensen was honored with the prestigious Knud Lundbæk award from the Scandinavian Society for the Study of Diabetes (SSSD) during its Annual Meeting in Helsinki on 24 May.
Read MoreSørasiater i Norge har høy risiko for type 2 diabetes, men mekanismene bak dette er ukjent. Vi sammenlignet derfor 179 sørasiatiske og 108 nordiske kvinner etter svangerskapsdiabetes.
Read MoreSuccess in achieving International Society for Pediatric and Adolescent Diabetes’ glycemic targets varies considerably among countries. This paper seeks to evaluate how HbA1c levels and the use of diabetes technology changed in Norway from 2013 to 2022 and how different measures influence glycemic control.
Read MoreCand.med. Maryam Saeed at Institute of Clinical Medicine will be defending the thesis “Risk of Coronary Heart Disease and End-Stage Renal Disease in Type 1 Diabetes with onset before 15 years of age, 1973 - 2017” for the degree of PhD (Philosophiae Doctor).
Read MoreThe use of tissue continuous glucose monitoring (CGM) has increased exponentially the last five years. In the Norwegian diabetes registries 96% of children and 87% of adults with type 1 diabetes in Norway use this technology. The New England Journal ogf Medicine recently had a review article on diabetes technology.
Read MoreResearchers from Oslo Diabetes Research Center today present the results of the DiVID study at the annual meeting of the European Association for the Study of Diabetes in Hamburg. The study was simultaneously published in the high-ranked medical journal Nature Medicine.
Read MoreM.Sc. Nicolas Fragoso Bargas at Institute of Clinical Medicine will be defending the thesis “DNA Methylation and cardiometabolic health: associations with insuline resistance, folate, and physical activity in pregnancy” for the degree of PhD (Philosophiae Doctor).
Read MorePresentations from members of Oslo Diabetes Research Center at EASD 2023.
Read MoreResearchers from our center will present news about diabetes and diabetes research to the public at a meeting in Litteraturhuset, Oslo on Tuesday September 26, at 6 p.m.
Read MoreOur Annual report from 2022 shows a highly active year.
Read MoreOn June 14th Oslo Diabetes Research Center celebrated the annual summer party.
Read MoreSindre Lee-Ødegård has been awarded NOK 16 million in the Excellence Emerging Investigator Grant in endocrinology and metabolism from the Novo Nordisk Foundation.
Read MoreOslo Diabetes Research Centre’s annual whole-day seminar was held on March 23.
Read MoreThe 57th Annual Meeting will be held 22nd to 25th of April in Soesterberg, the Netherlands.
The abstract deadline will be 15th of January 2023 (no extensions), with confirmation of acceptance before 1st of February 2023. Please visit www.edeg2023.nl to submit your abstract, and for more information about the meeting.
57th Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD2023) in Aarhus
The registration for the 57th Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD2023) in Aarhus, Denmark is now open https://ddeacademy.dk/events/57th-annual-meeting-scandinavian-society-study-diabetes-sssd2023. The Annual Meeting will be held 24-26 May 2023 at the new Steno Diabetes Center Aarhus.
We encourage all researchers/clinicians working within any field of diabetes to participate. Participants are encouraged to submit abstracts, and participation is guaranteed for all who have submitted an abstract. All accepted abstracts will be presented orally with two Outstanding Presentation Awards each of 5000 NOK awarded to the two best presentations.
The program will alternate between invited talks within different areas of diabetes research (complications, epidemiology, appetite regulation, adipose tissue, glucagon, lifestyle interventions), and short oral presentations from participants.
Priority will be given to networking and social events, which will be incorporated throughout the meeting, to facilitate and strengthen collaborative relationships. During the meeting, the annual SSSD research prizes are awarded with presentations from the prize recipients (Knud Lundbæk Award, SSSD Young Investigator Award, Novo Nordisk Foundation Lecture Prize and The Swedish Child Diabetes Foundation Nordic Prize).
Cand.med. Archana Sharma at Institute of Clinical Medicine will be defending the thesis “Glucose metabolism in South Asian and Nordic women with previous gestational diabetes mellitus” for the degree of PhD (Philosophiae Doctor).
Time and place: Jan. 19, 2023 12:15 PM, Store auditorium (Frontbygget), Akershus Universitetssykehus, Sykehusveien 25, Lørenskog
For more information, click Public Defence: Archana Sharma - Institute of Clinical Medicine (uio.no)
With data from the EPIPREG sample, we identified six cross-ancestry CpG sites related to insulin resistance in pregnancy, whereof five were replicated in independent studies. From methylation quantitative trait loci analysis, we identified gene variants related to all five replicated cross-ancestry CpG sites, which were associated with several cardiometabolic phenotypes. Mediation analyses suggested that the gene variants regulate insulin resistance through DNA methylation.
DIABETES, December 19th 2022, online ahead of print: Click here
Using data from 24 population-based data sources from Europe, Asia, North America, and Oceania, we estimated the lifetime risk of type 2 diabetes, life expectancy in people with and without type 2 diabetes, and years of life lost to type 2 diabetes. With the incidence of type 2 diabetes declining in the high-income setting, there has been a corresponding decrease in lifetime risk in many high-income jurisdictions.
However, the burden of diabetes remains high. This substantial individual burden should be considered in future public health strategy and emphasised in patient counselling to improve health outcomes for people with type 2 diabetes.
THE LANCET Diabetes and Endocrinology VOLUME 10, ISSUE 11, NOVEMBER 01, 2022
Astra-Zeneca og Norsk Endokrinologisk Forening har lyst ut forskningsmidler ment for å stimulere klinisk forskning i Norge innen terapiområdet diabetes.
Post-doc Sindre Lee-Ødegård ved UiO har søkt om midler for å gjennomføre proteom-kartlegging hos 60 personer med risiko for type 2 diabetes (kvinner av sør-asiatisk eller nordisk opprinnelse med tidligere svangerskapsdiabetes) med mål om å forbedre patofysiologisk forståelse, risiko-stratifisering og identifikasjon av mulige nye behandlingsmål/intervensjonsmuligheter. Prosjektet fremstår å være gjennomførbart, hvor søker kommer fra et faglig sterkt miljø og har en solid publikasjonsliste.
Tematisk tilhører prosjektet et spennende felt innen presisjonsmedisin, med potensiale for nye funn som på sikt kan ha klinisk nytte.
The team behind the DiViD study previously reported the presence of enterovirus (EV) genome and proteins in pancreatic sections from six live newly diagnosed patients with type 1 diabetes. In this issue, Krogvold et al (https://doi.org/10.1007/s00125-022-05779-2) confirm the presence of EVs and also demonstrate that no other common human viruses are present in the pancreases of the six DiViD cases.
The authors demonstrate that the EV strains detected represent live infectious viruses capable of establishing a persistent pancreatic infection. As previously shown in persistent EV infection of the heart, persistent EV infection of the pancreas could lead to progressive tissue-specific dysfunction. The authors conclude that the early phase of type 1 diabetes is associated with low-grade EV infection. They go on to suggest that the findings strengthen the need for studies exploring the potential benefits of enteroviral vaccines for individuals at high risk of developing type 1 diabetes and antiviral treatment for individuals in the early phase of type 1 diabetes
Powered by Squarespace.
